Group 1 - TATA Health (01255) announced the appointment of Mr. Tan Kaiguo as an independent non-executive director and chairman of the audit committee, effective from September 30, 2025 [1]

Group 1 - TATA Health (01255) announced the appointment of Mr. Tan Kaiguo as an independent non-executive director and chairman of the audit committee, effective from September 30, 2025 [1]

Group 1 - TATA Health (01255.HK) announced the appointment of Tan Kaiguo as an independent non-executive director, effective from September 30, 2025 [1] - Following the appointment of Tan Kaiguo as the chairman of the audit committee, Huang Lin will no longer serve as the chairman and member of the audit committee [1] - After the changes take effect, the audit committee will include Tan Kaiguo, Li Liang, and Du Jianfeng [1]

（於開曼群島註冊成立的有限公司） （股份代號：1255） 董事名單與其角色和職能 TATA健康國際控股有限公司董事（「董事」）會（「董事會」）成員載列如下： 非執行董事 朱俊豪先生 張鳴琪先生 陳琦先生 獨立非執行董事 黃琳女士 李亮先生 杜建峰先生 譚開國先生 TATA Health International Holdings Limited TATA 健 康 國 際 控 股 有 限 公 司 黃琳女士（主席） 李亮先生 杜建峰先生 香港，二零二五年九月三十日 董事會設立3個委員會。各董事會成員在這些委員會中所擔任的職位載列如下： 審核委員會 提名委員會 譚開國先生（主席） 李亮先生 杜建峰先生 薪酬委員會 黃琳女士（主席） 李亮先生 杜建峰先生 ...

董事會宣佈，譚開國先生已獲委任為獨立非執行董事及審核委員會主席，自二零 二五年九月三十日起生效。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 TATA Health International Holdings Limited TATA 健 康 國 際 控 股 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1255） (1)委任獨立非執行董事； (2)審核委員會組成之變更； 及 (3)符合上市規則第3.10(2)條及審核委員會職權範圍 (1) 委任獨立非執行董事 TATA健康國際控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事 （「董事」）會（「董事會」）欣然宣佈，譚開國先生（「譚先生」）已獲委任為獨立非執 行董事，自二零二五年九月三十日起生效。 譚先生的履歷詳情載列如下： 譚先生，52歲，在審計及金融管理領域擁有豐富經驗。譚先生曾於二零零零年 六月至二零零一年六月任職於立信會計師事務所（特殊普通合夥）。彼其後於二 零 ...

Core Insights - TATA Health (01255.HK) reported a revenue of HKD 124 million for the fiscal year ending December 31, 2024, representing a 40% year-on-year decline [1] - The company recorded a loss attributable to shareholders of HKD 68.34 million, which is an increase of 111.6% compared to the previous year [1] - Basic loss per share was HKD 0.28 [1] Revenue Analysis - The decline in revenue is primarily attributed to a decrease in the footwear business [1] - The challenging economic environment has led to weakened consumer sentiment, significantly impacting the retail sector in Hong Kong [1]

Core Viewpoint - TATA Health (01255.HK) reported a significant decline in revenue for the six months ending June 30, 2025, primarily due to a decrease in footwear sales amid challenging retail conditions in Hong Kong [1] Financial Performance - Revenue for the period was HKD 42.118 million, representing a year-on-year decrease of 41.8% [1] - The company reported a profit attributable to owners of HKD 20.596 million, a turnaround from a loss of HKD 5.13 million in the same period last year [1] - Basic earnings per share were HKD 0.08 [1] Business Segment Analysis - The decline in revenue was mainly attributed to reduced sales in the footwear segment [1] - Consumer sentiment has been weak, and ongoing economic uncertainty has created a challenging environment for the retail sector in Hong Kong [1]

Core Insights - TATA Health (01255) reported a revenue of HKD 42.118 million for the six months ending June 30, 2025, representing a year-on-year decline of 41.8% [1] - The company recorded a profit attributable to shareholders of HKD 20.596 million, compared to a loss of HKD 5.13 million in the same period last year [1] - Basic earnings per share were HKD 0.08 [1] Revenue Analysis - The decline in revenue was primarily attributed to a decrease in footwear business income [1] - The challenging environment for retail in Hong Kong was influenced by weak consumer sentiment and ongoing economic uncertainty [1]

Core Insights - TATA Health (01255) reported a revenue of HKD 42.118 million for the six months ending June 30, 2025, representing a year-on-year decline of 41.8% [1] - The company achieved a profit attributable to shareholders of HKD 20.596 million, compared to a loss of HKD 5.13 million in the same period last year [1] - Basic earnings per share were HKD 0.08 [1] Revenue Analysis - The decline in revenue was primarily attributed to a decrease in footwear business income [1] - The challenging environment for retail in Hong Kong was influenced by weak consumer sentiment and ongoing economic uncertainty [1]

Group 1 - TATA Health (01255) reported an annual performance for the year ending December 31, 2024, with revenue of HKD 124 million, a decrease of 40% year-on-year [1] - The company recorded a loss attributable to shareholders of HKD 68.338 million, which represents a year-on-year increase of 111.6% [1] - Basic loss per share was HKD 0.28 [1] Group 2 - The decline in revenue compared to the fiscal year 2023 was primarily due to a decrease in footwear business revenue [1] - The reduction in footwear business earnings was mainly attributed to ongoing economic uncertainty, which has weakened consumer sentiment, creating a challenging environment for the retail sector in Hong Kong [1]